Samrat Pharmachem Ltd Stock Price Today (NSE: SAMRATPH)
Fundamental Score
Samrat Pharmachem Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Samrat Pharmachem Ltd share price today is ₹198.30, down 1.64% on NSE/BSE as of 17 June 2026. Samrat Pharmachem Ltd (SAMRATPH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹75.79 (Cr). The 52-week high for SAMRATPH share price is ₹389.00 and the 52-week low is ₹190.00. At a P/E ratio of 48.58x, SAMRATPH is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 10.07% and a debt-to-equity ratio of 0.15.
Samrat Pharmachem Ltd Share Price Chart — NSE/BSE Historical Performance
Samrat Pharmachem Ltd share price chart: 7.83% return over the past month. 52-week high ₹389.00, 52-week low ₹190.00.
Samrat Pharmachem Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹233.70 | ₹238.80 | ₹220.00 | ₹225.90 | 849.00 (Cr) | |
| ₹231.85 | ₹238.25 | ₹230.00 | ₹232.55 | 1.30K (Cr) | |
| ₹230.00 | ₹241.00 | ₹230.00 | ₹232.25 | 2.76K (Cr) | |
| ₹221.05 | ₹225.85 | ₹221.00 | ₹224.55 | 1.01K (Cr) | |
| ₹208.60 | ₹234.00 | ₹208.55 | ₹222.00 | 8.59K (Cr) | |
| ₹213.95 | ₹213.95 | ₹208.00 | ₹208.55 | 105.00 (Cr) | |
| ₹212.00 | ₹213.95 | ₹202.00 | ₹213.35 | 1.47K (Cr) | |
| ₹208.00 | ₹216.85 | ₹208.00 | ₹212.70 | 477.00 (Cr) | |
| ₹210.00 | ₹217.80 | ₹207.00 | ₹209.50 | 2.08K (Cr) | |
| ₹212.95 | ₹218.95 | ₹208.10 | ₹208.60 | 847.00 (Cr) |
Samrat Pharmachem Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹215.05 | ₹241.00 | ₹202.00 | ₹225.90 | +5.05% | |
| ₹198.95 | ₹230.80 | ₹192.65 | ₹211.10 | +6.11% | |
| ₹200.00 | ₹243.85 | ₹190.00 | ₹194.95 | -2.53% | |
| ₹203.50 | ₹255.60 | ₹200.00 | ₹209.40 | +2.90% | |
| ₹234.50 | ₹238.00 | ₹195.10 | ₹200.50 | -14.50% | |
| ₹250.00 | ₹270.00 | ₹224.00 | ₹227.30 | -9.08% | |
| ₹290.85 | ₹294.70 | ₹251.00 | ₹255.40 | -12.19% | |
| ₹297.00 | ₹320.00 | ₹271.10 | ₹290.85 | -2.07% | |
| ₹320.25 | ₹333.00 | ₹289.00 | ₹291.50 | -8.98% | |
| ₹340.00 | ₹355.00 | ₹314.00 | ₹324.95 | -4.43% | |
| ₹359.00 | ₹389.00 | ₹340.00 | ₹342.95 | -4.47% | |
| ₹331.00 | ₹378.95 | ₹331.00 | ₹358.85 | +8.41% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Samrat Pharmachem Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Samrat Pharmachem Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SAMRATPH across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Consistent Growth Track Record (15.77% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.15)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Premium Valuation Risk (P/E: 48.58x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-122.18%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Institutional Interest (FII+DII: 3.24%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Samrat Pharmachem Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Samrat Pharmachem Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Samrat Pharmachem LtdSamrat Pharmach...Selected✓ SAMRATPH • 530125 | 38.1/100 | ₹198.30₹198 | ₹75.79₹75.79 | 48.58Average 48.6 Average | 10.07%Average 10.07% Average | 13.21%Average 13.21% Average | 0.15Excellent 0.1 Excellent | 10.15%Good 10.15% Good | 15.77%Excellent 15.77% Excellent | 0.41% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Samrat Pharmachem Ltd PE Ratio History
Historical price-to-earnings ratio for SAMRATPH — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹7.00 | ₹382.65 | 54.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Samrat Pharmachem Ltd Dividend History
Annual cash dividends paid by SAMRATPH — dividend yield 0.41%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹0.31 Cr |
| FY 2024 | ₹0.31 Cr |
| FY 2023 | ₹0.31 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Samrat Pharmachem Ltd Quarterly Performance
Latest quarterly metrics for SAMRATPH — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
12.40%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-122.18%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
15.77%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
10.15%
Compounded annual net profit growth over 5 years
Samrat Pharmachem Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SAMRATPH — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Samrat Pharmachem Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Samrat Pharmachem Ltd (SAMRATPH) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Samrat Pharmachem Ltd
About SAMRATPH (Samrat Pharmachem Ltd)
Samrat Pharmachem Ltd is a stalwart in the Indian pharmaceutical landscape, deeply rooted in the production and distribution of a diverse array of pharmaceutical chemicals. Their o...perations hum with a precision that reflects decades of experience, crafting specialized iodine-based compounds and related substances vital to numerous sectors. Think of them as the silent engine providing the essential building blocks for medications, diagnostic tools, and research applications across the nation and beyond. Samrat Pharmachem doesn't directly create finished medicines, but their contribution is indispensable, ensuring a steady and reliable supply of high-quality chemical ingredients that underpin the medical industry. The company's portfolio is a testament to their mastery of iodine chemistry, encompassing a wide spectrum of iodides, iodates, and related compounds. They meticulously synthesize everything from the foundational hydroiodic acid and elemental iodine to more complex molecules like clioquinol and iodoquinol, each meticulously tested and refined to meet stringent industry standards. Their product list is not exhaustive, it includes various metallic iodides like copper iodide and cadmium iodide, alongside organic iodides such as ethyl iodide and methyl iodide. Samrat Pharmachem also demonstrates its ability to cater to diverse needs with offerings like povidone iodine, commonly found in antiseptic solutions, highlighting their dedication to serving a broad range of pharmaceutical requirements. Samrat Pharmachem Ltd functions as a cornerstone in the supply chain, providing the raw materials that empower pharmaceutical companies to develop and manufacture life-saving and life-improving medications. They are the unsung heroes who contribute to advancements in healthcare with their dedication to chemical excellence. Their sustained success lies in their capacity to consistently deliver quality products, establishing them as a trusted and dependable partner for pharmaceutical manufacturers throughout India and in select international markets. The company's presence ensures the continuous availability of vital chemical substances and supports the growth and development of the wider pharmaceutical industry.
Company Details
Key Leadership
Corporate Events
SAMRATPH Share Price: Frequently Asked Questions
What is the current share price of Samrat Pharmachem Ltd?
Samrat Pharmachem Ltd (SAMRATPH) trades at ₹198.30 on NSE and BSE. Market cap ₹75.79 (Cr). Educational data only.
What is the P/E ratio of Samrat Pharmachem Ltd?
Samrat Pharmachem Ltd has a P/E of 48.58x vs industry average 31.77x.
What is the Bull Run score for Samrat Pharmachem Ltd?
Samrat Pharmachem Ltd has a Bull Run score of 38.1/100 based on 25+ financial parameters.
Does Samrat Pharmachem Ltd pay dividends?
Samrat Pharmachem Ltd has a dividend yield of 0.41%. Past dividends don't guarantee future payments.
What is the ROE of Samrat Pharmachem Ltd?
Samrat Pharmachem Ltd has ROE of 10.07%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Samrat Pharmachem Ltd?
Samrat Pharmachem Ltd has debt-to-equity of 0.15.
Is Samrat Pharmachem Ltd a good investment?
Bull Run gives Samrat Pharmachem Ltd a score of 38.1/100. This is not investment advice — consult a SEBI-registered advisor.